DE-RISKING COMBINATION PRODUCT REGISTRATION FOR SEMI-SOLIDS WITH APTAR PHARMA’S AIRLESS+ SYSTEM – AN INTERVIEW WITH STEFAN HELLBARDT
Daryl Bassett and David Barnes show how the choice of common excipients can have a material impact on manufacturing success, quality and, ultimately, commercial success for topical formulations, which generally require the incorporation of more excipients than other products to deliver their API payload effectively.
Christophe Marie, Taylor Price and Julien Storz chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.
Nicky Bertollo, Ronan Byrne and Andrew Muddle introduce Pharma Latch – a user-centric angled microneedle patch technology. They discuss its key benefits, such as dramatically increased payload potential, precision, low cost and variable patch-wear times, and highlight how Pharma Latch has the potential to overcome many of the limitations of existing routes of administration for therapeutics and vaccines.
In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.
VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH